United States: New York

Firms: litigation

Firms: prosecution

  • Baker Botts LLP
  • Dechert LLP
  • Fay Kaplun & Marcin LLP
  • Fish & Richardson
  • Fox Rothschild LLP
  • Greenberg Traurig LLP
  • Haley Guiliano LLP
  • King & Spalding LLP
  • Leason Ellis LLP
  • Pearl Cohen Zedek Latzer Baratz 
  • Steptoe & Johnson LLP

Firms: transactions

Alston & Bird LLP

Alston & Bird’s New York lawyers continue to do their thing in the life sciences space, litigating important, multi-patent cases for high-profile clients. For Sandoz and Lek Pharmaceutical, for example, the team is battling to give them the opportunity to be first to market with a generic version of the IMBRUVICA cancer drug. However, the suits taken on by the group are diverse in terms of industry sector, technical subject matter and forum. Recently, Ford retained it to defend an action brought by the Massachusetts Institute of Technology and Ethanol Boosting Systems alleging infringement of four patents relating to Ford’s EcoBoost engines. Natalie Clayton, who spearheads the biotechnology and pharmaceutical patent litigation team (and who is representing Sandoz in the abovementioned matter), was brought in on this one as a crack litigator who knows the District of Delaware well. Clayton has spent her entire career at Alston & Bird and has flourished there. She has tried many cases and has the judgement to know what is and what is not material – she does not chase down rabbit holes, but focuses intensely on things that will move the needle.

Arnold & Porter Kaye Scholer LLP

In the ultra-competitive life sciences patent litigation arena, Arnold & Porter more than holds its own and shines for its strategically sophisticated approach and impressive hit rate. Recent highlights include a significant victory for Sanofi and Regeneron in the retrial of a patent action brought by Amgen in Delaware against cholesterol-reducing antibody drug Praluent. Seasoned patent and trade secret litigators David Barr and Daniel Reisner fought this alongside DC’s Matt Wolf and Silicon Valley’s Deborah Fishman, making it a prime example of the collaborative approach the firm utilises to pull off big wins. At the same time, Aaron Stiefel and Daniel DiNapoli – other vaunted veterans of the practice – have been handling Hatch-Waxman litigations for long-time client Pfizer concerning various blockbuster products, including Viagra and Celebrex.

Axinn, Veltrop & Harkrider LLP 

It is not unusual for Axinn to be asked to take over from other firms mid-litigation; when the fact pattern is complex, the technology dense, the law uncertain or the commercial risk high, it has the moxie to get the job done and emerge victorious. Testament to this is an exceptional track record in pharmaceutical patent cases, to which new highlights are constantly added. Aggressive tactics get Chad Landmon the business-driven results he looks for; he moves fast and puts opponents in the hurt locker, creating a threat level that often forces plaintiffs into settlement. He is nimble, too, and can adjust strategies when circumstances change. Landmon adds tremendous value with his rich regulatory knowledge; he chairs both the IP and the Food and Drug Administration (FDA) practices. One of his most trial-savvy colleagues is managing partner Matthew Becker, with whom he recently teamed up to represent Alvogen Malta Operations against Pernix Ireland Pain DAC and Pernix Therapeutics; the patent claims asserted by the latter were found to be invalid due to obviousness and failure to satisfy the written description requirement, removing them as a barrier to Alvogen bringing its generic product to market more than a decade before the expiry of the patents. Even-keeled, steady and calm under pressure describes Becker. Also highly rated is David Silverstein, a former in-house senior IP director with an inside view of the business of the pharmaceutical and biotech industries. He does it all – takes lead counsel roles, supervises transactional affairs and counsels on patent strategy and regulatory affairs – and does it well. “David gets you what you need while keeping within budget. He manages staffing effectively and offers alternative billing models as appropriate – the extremely high quality of his customer service matches that of his work.”

Baker Botts LLP

By practising in a multidisciplinary way, Baker Botts sees the whole patent landscape and can provide salient solutions whatever issues come up and however the law develops. Its well roundedness also puts it in pole position for post-grant proceedings success, of which it has enjoyed much lately. Though there has been a modest reduction in patent litigation industry-wide, Baker Botts has continued to attract good cases. For example, smart trial lawyers Neil Sirota and Robert Maier have had a string of recent trial and dismissal defence wins for longstanding patron Samsung Electronics; other Korean companies have taken note, leading to increased outreach from the Asian peninsula. Both receive enthusiastic reviews: “Elevating his service, Neil understands company culture and politics. He works extremely hard and responds to emails at all hours of the day and night, and he gets great results while staying in budget.” “Rob can always be counted on to provide clear, business-focused advice. He’s deeply knowledgeable and has an approachable style that makes him a pleasure to partner with.” Robert Scheinfeld, meanwhile, recently settled global litigation for Fujifilm against Sony relating to magnetic data storage tapes and cartridges; this required pulling major weight at the International Trade Commission (ITC) – another favourable forum for the firm of late. Underscoring this versatility, Maier and Scheinfeld also handle prosecution; together they act for Hitachi across the contentious/non-contentious divide. One of the most complete patent lawyers on deck is Paul Ragusa; he does everything for Columbia University, including counselling around SEPs – a subject on which he is a leading authority. “Paul is a consummate professional and the king of client service – he delivers exactly what you need when you need it, and for a very reasonable cost.” A deft handler of large portfolios and a transactional IP expert, Daniel Hulseberg is exceptionally rangy, too.

Cravath, Swaine & Moore LLP 

Cravath is a lion of the legal market and a stand-out performer in the patent litigation and transactional theatres. Its lawyers have an unstinting dedication to winning and work insane hours to get the toughest jobs done. Unstoppable force Keith R Hummel has multiple once-in-a-lifetime-type accomplishments on his résumé – and he is always adding new ones. A particularly eye-catching recent example was a jury verdict he secured for Amgen as plaintiff in a case against Sanofi, Sanofi affiliates and Regeneron confirming the validity of Amgen patents on its ground-breaking cholesterol-lowering drug Repatha; called in special forces-style for this retrial – which was closely watched as a significant test of the validity of genus claims covering categories of antibodies – Hummel once again displayed the obsidian-sharp trial skills he used previously to represent Amgen in litigation concerning its introduction of a biosimilar to AbbVie’s Humira. Sharing the load on this was chemical, pharmaceutical and biotech litigation ace David Greenwald. The elite generalist training that Cravath’s trial lawyers receive not only supercharges their advocacy skills, but also puts them in a unique position to handle lawsuits in which intersecting legal issues ramp up the complexity. David R Marriott took the lead in one such recent matter, representing Mylan in a consolidated set of antitrust lawsuits concerning alleged reverse-payment settlement agreements between Cephalon and generic drug manufacturers. Marriott has been hammering it recently and acted for Qualcomm in two ITC actions against Apple seeking to bar iPhones containing non-Qualcomm wireless modem chips from entering the United States – suits that were ultimately resolved by a global settlement reached between the two companies in April 2019. Having acted for Qualcomm throughout its fight with Apple, firm chairman Evan R Chesler and Richard J Stark were by the chipmaker’s side negotiating the commercial terms of the settlement, which resulted in a $4.7 billion payment from Apple and the release of certain associated liabilities. As in litigation, it has been a huge 12 to 18 months on the transactional side, too – highlighted by representation of the Walt Disney Company in its $85 billion acquisition of Twenty-First Century Fox, which involved the distribution and cross-licensing of assets in all IP classes. David J Kappos is a dealmaker like no other, given his global patent view. Lately, he has been showing vital leadership on data-driven transactions which require the cross-disciplinary expertise and antitrust abilities that only Cravath can supply.

Davis Polk & Wardwell LLP

A new addition to the IAM Patent 1000 New York rankings for 2020, Davis Polk & Wardwell runs a premier IP and technology transactions group, which stands alone while also supporting the firm’s top-tier corporate M&A and capital markets practices. The group has built up a lot of momentum, thanks to hires that have bolstered its life sciences and media transactional capabilities. The go-to for pharmaceutical and biotech deals and collaborations is bioscience PhD David Bauer. His recent highlights include advising Novo Nordisk on its $145 million acquisition of the US and Canadian rights to Macrilen from Strongbridge Biopharma. Head of the group Frank Azzopardi works extensively in media, but also in other fields, including finance, healthcare and information technology. He has a strong foundation in intellectual property broadly and is a good fit for negotiations encompassing the transfer of brands and patents.

Dechert LLP

Ascending to the IAM Patent 1000 silver tier for litigation in New York, Dechert is on a roll in the life sciences right now. Flexible and entrepreneurial, it has mastered the fine art of co-counselling with others on sprawling pharmaceutical patent cases, but also has the expertise and gravitas to take the lead. Litigators Noah Leibowitz and Katherine Helm have been off to the races since they came on board in 2018. They combine well, as they showed getting Daiichi Sankyo out of long-running pay-for-delay litigation over generic Lipitor with zero liability. Leibowitz is hailed for the business sense he brings to litigation, cultivated through extensive involvement in transactional IP practice. Former Simpson Thacher lawyer and neuroscience PhD Helm is gifted at handling global lawsuits and makes judicious use of the firm’s prosecution resources in cases with concurrent patent office proceedings. Great assets in this regard are Carl Morales and Samuel Abrams, both wonderful counsellors and prosecutors with abundant post-grant experience – Morales under the America Invents Act and Abrams in interferences and European oppositions. Coming in for praise, synthetic and organic chemistry PhD Morales is “extremely cost conscious and tremendously creative”. A good recent example of his commercially important work is the patent protection he secured on behalf of Pfizer for Ibrance, a blockbuster breast cancer treatment. Adding immense depth to the ensemble’s life sciences offering is Stephen Rabinowitz, another relatively new arrival alongside Leibowitz and Helm. Among pharmaceutical litigators, he is as good on the science as they come.

Desmarais LLP 

When everything is on the line, Desmarais is the firm to call: its trial lawyers are the best trained in the business and there is plenty of them, too – all with superb track records in court. They understand precisely the relative merits of different possible arguments at different stages of a case and score their points in the timeliest and most impactful way; they couple this skill with the ability to simplify technology and law and really connect with juries on a one-to-one level. In recognition of its depth, the side receives extended coverage in the IAM Patent 1000 for 2020, with Karim Z Oussayef, Laurie Stempler and Tamir Packin all making their debuts. Oussayef and Stempler have been on the frontlines of cases for IBM and recently secured a $82.5 million victory after a Delaware jury found that Groupon had wilfully infringed IBM’s asserted e-commerce patents. Packin, meanwhile, earned a major trial win for Cisco Systems when a federal judge invalidated all asserted claims of a virtual networking patent asserted by Egenera. Seamless teamwork is a hallmark of the firm’s approach to complex cases; on the IBM matter, Oussayef and Stempler operated alongside John M Desmarais; while Packin linked up with Jonas R McDavit and California-based Peter Magic, who also makes his first appearance in the guide this year. John Desmarais is “so good at trial that he intimidates a lot of companies into settling out”. He and McDavit “don’t push decisions, but dig in from day one of a case to figure out how to try and win it”. Other lead trial lawyers receiving abundant praise are Paul A Bondor and Alan S Kellman. Bondor is “exceptionally hands-on for a senior trial lawyer. He’s responsive, engaged and attentive, and demonstrates sound judgement and thoughtfulness.” He has also been doing great things for Cisco: hours before opening trial statements were to be given, he hammered out a settlement in an antitrust lawsuit brought by Arista Networks under which Arista agreed to pay Cisco $400 million and to withdraw all its antitrust claims. Kellman “is absolutely outstanding in court, with a clear, calm and well-mannered style of advocacy. He tells stories that people can understand and relate to, and does a fantastic job with evidence and in cross-examinations. He also runs an efficient case, assembling small but extremely capable teams of associates. He clearly has an eye for young talent and is also brilliant with technology.”

Fay Kaplun & Marcin LLP

“In-house counsel have really bought into Fay Kaplun, a boutique that is doing great work for top companies.” “The quality of its service is at the same level, or better, than that provided by much larger and more established names, but it charges one-third of the price.” Throughout all phases of patent prosecution, Oleg Kaplun is a vital partner to high-tech companies in the hardware, software, e-commerce and wireless communication spaces.

Fenwick & West LLP

Fenwick & West’s New York pharmaceutical litigation practice – and broader high-tech patent litigation offering – is going from strength to strength; on a repeat basis, prestigious life sciences and other companies dial up seasoned trial lawyers Jeffrey Oelke, James Trainor and Kevin McGann for representation in high-stakes competitor cases. Oelke and Trainor, for example, recently went out to bat for Pfizer against Mylan Pharmaceuticals, winning on all claims and defences with respect to Mylan’s challenge of five patents covering the drug TOVIAZ, with a superlative PTAB effort contributing to the victory. Against opponents, Oelke and Trainor have been very successful leveraging inconsistency in positions taken by different generics challengers. Forming a potent battle group with Adam Gahtan and McGann, Trainor has also been acting for LTS Lohmann Therapie-Systeme and a multinational biopharmaceutical company in Hatch-Waxman litigation involving a product for the treatment of Parkinson’s. Gahtan has litigated IP and non-IP cases for pharmaceutical companies and is a well-rounded problem solver for it. McGann also has broad horizons and serves as a litigator and patent strategy and business counsellor to his followers, including several technology industry leaders. Not just litigation focused, Fenwick & West is one of the increasingly rare commercial firms in New York on call on for patent procurement. Helming the prosecution practice locally, Daniel Brownstone counsels Dropbox on software patents and Section 101 issues, while providing incisive advice to many other consumer-facing technology brands.

Fish & Richardson

Innovators from all walks of commercial life can get any patent-related service they need from Fish & Richardson’s excellent New York office. Prized assets for pharmaceutical and biotech entities include Tony Zhang and Jack Brennan, two versatile operators who know the business of the life sciences well. Chemistry PhD Zhang, whose practice has been incredibly dynamic of late, has been capitalising on this commercial astuteness to guide a Fortune Global 500 healthcare and pharmaceutical company on business and litigation risk. For financial services companies, Michael Zoppo serves as IP concierge – whether infringement problems need fixing, portfolio questions need answering or deals need striking, he has the measure of the situation and is there with solutions. Established and emerging high-tech companies have an ally in Samuel Borodach, another ambidextrous lawyer who contributes significantly to Fish’s success in prosecution and post-grant proceedings.

Fox Rothschild LLP

Fox Rothschild’s cohesiveness across offices and practice groups is a boon to life sciences and medical device entities seeking holistic support on US and global patenting matters. The New York team, which is growing in both headcount and visibility, is rich in talent and receives exemplary leadership from Janet MacLeod, a registered patent attorney specialising in the global acquisition and enforcement of pharmaceutical and biotech patents. “Janet has spectacular scientific knowledge and is very even-keeled. She performs with the utmost professionalism and attention to detail, and produces high-quality work quickly.” Her academic followers include Mount Sinai School of Medicine and Rutgers University, which she supports on international prosecution; corporate clients include Lytix Biopharma and Kwoya Hakko Bio, whose successful IP commercialisation efforts bear her fingerprints. Deborah Somerville is also on the shortlist of top patent attorneys who can drive business gains. She sees subtle shifts in the marketplace and designs clever strategies to help patrons exploit them. Joining them in the guide for the first time this year is Dianna El Hioum, who joined the firm in April 2018, having previously been at Merchant & Gould for eight years. Upon arrival, she found the division to be extremely well run from docketing and other perspectives and has settled in terrifically, expanding her practice representing life sciences companies and firearms manufacturers. She is intimately familiar with their industries – who the key players are and what they are doing – and is a well-connected, broad-minded counsellor.

Gibson Dunn & Crutcher LLP

Solid gold for litigation, Gibson Dunn acquits itself with rare distinction on the cases that count. “All of its lawyers are thoughtful, careful, top-notch litigators and leaders in their field. Their theoretical understanding of cases is outstanding, and they really know how to execute in the courtroom.” The first name on the team sheet is IP co-chair Josh Krevitt, a hard-hitting trial lawyer who embodies the firm’s laser-targeted, decisive approach – he does not waste energy making non-dispositive arguments. Together with fellow New Yorkers Benjamin Hershkowitz and Brian Rosenthal, he has recently been litigating an 11-patent, 500-claim battle for EMC against ACQIS that spans two district courts, multiple PTAB proceedings and the Federal Circuit – exactly the sort of multilayered dispute that Gibson Dunn is engineered for; one success along the way was the transfer of the case out of the Eastern District of Texas to EMC’s home in the District of Massachusetts. No patent litigation outfit can claim membership of the elite without a well-cultivated life sciences capability; affording Gibson this are Daniel Thomasch, Jane Love and Robert Trenchard. American College of Trial Lawyers (ACTL) fellow Thomasch is an arch-strategist for the group’s most complex multi-jurisdictional cases. Love and Trenchard pair up well and recently successfully represented Novartis in asserting a patent on the active ingredient for its best-selling multiple sclerosis drug Gilenya, thereby significantly limiting the doctrine of obviousness-type double patenting established by the maligned Gilead v Natco decision. Love is the person to call for an authoritative take on biologics issues and advice on the Biologics Price Competition and Innovation Act.

Goodwin Procter LLP

The strategic insight that Goodwin Procter can bring to pharmaceutical patent litigation is unmatched. Working on both the branded and generic sides, the firm is ideally placed to counter whatever moves opponents make; it is also abundantly demonstrating thought leadership with respect to legal, business and regulatory developments relating to biologics and biosimilars. Forming one of the best life sciences teams not just in New York, but in the country are Elizabeth Holland, Robert Cerwinski, Huiya Wu, Ira Levy and Alexandra Valenti. Someone who has set many benchmarks in US and global life sciences litigation, Holland has recently been serving as lead trial counsel for defendant Actavis in a series of Hatch-Waxman cases brought by Cosmo Technologies and Valeant Pharmaceuticals on the drug Uceris; as a result of her cogent and compelling advocacy, Actavis has been able to continue selling its product. Her experience has taught her how to read judges and understand their temperaments. Cerwinski, who ascends to the gold tier this year, co-founded the firm’s Big Molecule Watch blog and is right on the frontlines of biologics developments. His relevant recent work includes representing Celltrion and Teva Pharmaceuticals, together with Holland, in inter partes review and litigation proceedings involving their trastuzumab biosimilar product. Wu, who co-led the development of the Big Molecule Watch China companion blog, garners glowing notices: “Super-clever, highly persuasive and thoughtful, Huiya is a top-notch advocate and trusted adviser who helps you achieve your key business objectives.” Cross-disciplinary and cross-technology IP star Levy has also been litigating with Cerwinski, earning a Federal Circuit win for Dr Reddy’s Laboratories vacating a preliminary injunction that had halted its launch of generic Suboxone sublingual films. An up-and-coming star in the life sciences domain, Valenti has all the details of her cases at her fingertips and is great at keeping everyone looped in. She works in other areas, too, and recently partnered with Mark Abate to carry the day for Gillette in litigation against Dorco Co, Pace Shave and Dollar Shave Club. A heavyweight of the practice, Abate is an excellent mentor to the likes of Valenti and fellow rising star Calvin Wingfield, with whom he has been representing long-time client IBM. Newly minted partner Wingfield comes from a computer science background and looks set for great things in the practice.

Greenberg Traurig LLP

Despite a continuing overall decline in patent litigation, there is still a lot of great competitor cases out there and Greenberg Traurig is attracting more than its fair share of them. Placing a premium on culture, co-managing shareholder of the New York office and co-chair of the global patent litigation group Scott Bornstein has the team functioning collaboratively and with great energy. Teva is among those benefiting from the set’s dynamism and is partnering with Bornstein, Jonathan Ball, Richard Pettus, Allan Kassenoff and Joshua Raskin on a slew of Paragraph IV abbreviated new drug application challenges. All those named are highly accomplished patent litigators across myriad technologies and industries, who think not only about trial, but also about how to solve legal problems holistically while utilising the firm’s ample resources to their best advantage. They staff matters in the most effective and cost-efficient way from across the firm’s many US offices, while designing tailored fee structures that make sense for all parties. In terms of recent developments, the group has forged a reputation among Chinese companies as a destination of choice for US district court and ITC litigation. Joining her colleagues in the guide this year, Rose Cordero Prey is an “effective team worker who knows how to make her clients look good”. “She is becoming a real mover and shaker in litigation practice.”

Haley Guiliano LLP

Patent boutique Haley Guiliano is really going places: it has added astutely to its eminent New York life sciences practice by bringing pharmacology PhD Karen Mangasarian on board and significantly enhanced its litigation capabilities by adding polished trial lawyer Rick McCaulley in San Jose; at the same time, it has substantially increased the size of its London office, too. With these moves, it presents a well-rounded international offering to the marketplace defined by quality and cost-effectiveness. Spearheading the pharmaceutical and biotech practice is industry veteran James Haley, who “brings decades of experience in the law and a deep understanding of science to the table”. “Jim provides outstanding strategic guidance in prosecution that yields valuable patent assets and helps you to make wise choices with regard to your portfolio.” He coordinates worldwide filing for Agene Bio; prosecutes for AbbVie; and serves as global patent counsel for Tonix Pharmaceuticals. He also provides sterling representation in inter partes reviews. Haley’s counterpart in the high-technology realm is the seasoned and knowledgeable Joseph Guiliano.

Haug Partners LLP

Distinguished by the sophistication of its commercial and IP litigation practices, Haug Partners is ideally situated to handle cases in which complex patent, regulatory, antitrust and commercial issues intersect, thanks to the leadership of Edgar Haug and Porter Fleming. Chairman Haug brings gravitas to the courtroom; with extensive success in bench and jury trials in the United States and the United Kingdom, and in German litigation proceedings, he delivers arguments with authority. Unstinting in his dedication to clients and commercially impactful litigation outcomes, Fleming is a dyed-in-the-wool trial lawyer. They recently welcomed former Fitzpatrick lawyer and decisive pharmaceutical litigator Brian Slater into the fold.

Hughes Hubbard & Reed LLP

In fast-moving suits requiring strategic creativity, Hughes Hubbard & Reed always hits home runs. Its gifted advocates do not merely turn on the litigation machine and let it run; they listen to clients attentively to understand their business problems or the goals they wish to achieve, and then work towards their resolution or satisfaction with zeal. James Dabney is passionate about the law and where it is heading, which shines through in his advocacy. Leveraging an encyclopaedic knowledge of Supreme Court case law – some of which he has contributed to – “Jim is among the most creative lawyers in intellectual property today”. “He has a gift for seeing inconsistencies in longstanding rules of law, challenging them and then winning. He has been behind more significant legal changes than virtually any other litigator.”  His colleague Patrice Jean “works quickly and efficiently. She has an excellent ability to partner with business people on complex patent matters and to explain the law and technologies to non-experts”. Together, they scored a major recent victory for SNF Group against BASF when a Georgia court invalidated a BASF patent and dismissed a patent infringement action in which it sought more than $200 million in damages; there was a complex venue law backstory to this one, but Dabney – who served as lead counsel for TC Heartland in its precedent-setting case against Kraft Foods – and Jean were able to get the desired result.

Hunton Andrews Kurth LLP

Hunton Andrews Kurth stays steady for loyal patrons such as Volkswagen Group of America and Sony; these industry titans, among others, call on a repeat basis, knowing that the team here is 100% on their side and looking out for their best business interests. Putting clients first while executing adroitly on tight litigation strategies are Michael Lennon and Clifford Ulrich, who pair up for Volkswagen; and John Flock, who takes charge for Sony. Lennon’s transactional smarts make him highly effective at resolving conflicts in commercially satisfying ways; do not be fooled, though, as he is an extremely experienced senior trial counsel. Ulrich is vital to the success of the group’s mission as its top post-grant mind. Flock has been exceptionally consistent over the years, though a notable recent development in his practice is an uptick in trade secret litigation: he has counselled extensively on trade secret policies and approaches, and so has a full understanding of the issues.

Jones Day

Jones Day leaves pharmaceutical and biotech companies wanting for nothing when it comes to a well-rounded patent service. In Adriane Antler, clients have a repository of trust for global patent prosecution, portfolio management, post-grant and contractual IP matters; while in John Normile and Pablo Hendler, they have veteran life sciences litigators at their disposal. Normile and Hendler are currently representing Purdue Pharma in a Hatch-Waxman patent infringement action against Intellipharmaceutics relating to OxyContin.

King & Spalding LLP

Under the direction of exalted trial lawyer Gerald Flattmann, King & Spalding has built up one of the most vibrant pharmaceutical patent litigation practices in New York. Forming a well-organised team attuned to industry developments, Flattmann and rising stars Evan Diamond and Vanessa Yen have been on an impressive run of form. For example, they recently emerged victorious from a Hatch-Waxman litigation representing Galderma as plaintiff against Amneal Pharmaceuticals, thereby protecting the client’s successful rosacea treatment Oracea – a widely covered result as a doctrine of equivalents infringement ruling in the Hatch-Waxman context; the trio also prevailed for Galderma with respect to Oracea in a case against Sun Pharmaceutical Industries. The team has additionally been performing at a high level representing Alexion as patent owner in inter partes review proceedings challenging Alexion’s biologic product Soliris. Anchoring the high-tech-focused practice in New York, meanwhile, is Allison Altersohn, whose background in electrical engineering makes her well suited to technically intricate networking and computer-related cases. As a portfolio developer and licensing expert, she understands the business value of patents and never loses sight of this in litigation.

Kirkland & Ellis LLP 

“It’s no secret that Kirkland & Ellis’s patent litigation offering is top of the line. It has a deep team that can crunch through the toughest cases thoroughly and effectively.” “The firm has been extremely consistent in the practice, while a lot of its competitors have performed unevenly. If you have it on the other side, you know the case will be extremely hard fought, but in a civilised fashion.” The main draw in New York is Gregory Arovas, a lawyer hailed as one of the city’s – and the country’s – greatest patent trial advocates, with a confidence-inspiring track record in touch-and-go competitor battles. His recent instructions include representing Intel Corporation in patent litigation brought by Japanese IP fund Godo Kaisha IP Bridge 1 alleging infringement of patents on semiconductor chips; in this, Arovas demonstrated his superior teamwork and leadership skills by coordinating effectively not only with Kirkland colleagues in San Francisco, Los Angeles, Palo Alto and Chicago, but also with local counsel on related litigation in Japan; he also played a smart strategic game both in US district courts and at the PTAB to ultimately drive a dismissal of the case with prejudice and a favourable settlement. One of his ongoing representations includes acting for Charter Communications against Sprint Communications, which he is handling with a stalwart local crew including Jeanne Heffernan and Robert Appleby, both of whom have silky presentation skills honed over the course of diverse IP litigations. On the life sciences side, Patricia Carson continues to burn brightly, acting for top pharmaceutical and biotech innovators in jury and bench trials. Kirkland clients can also mine a rich seam of patent and technology transactions expertise, which is supplied in New York by David MacDonald. He has been lighting up the life sciences and technology spaces recently, brokering major deals and collaborations with significant industry impact. Among his notable accomplishments from 2019, he represented Danaher Corporation in its acquisition of General Electric’s GE Biopharma division for $21.4 billion in cash consideration to make Danaher a heavyweight in the field of bioprocessing.

Latham & Watkins LLP

A member of the patent litigation nobility, Latham & Watkins debuts in the IAM Patent 1000 New York firm rankings for 2020. Key members of both its life sciences and high-tech practices are stationed in the city and working on must-win cases involving cutting-edge technologies. Daniel Brown is the person that pharmaceutical and biotech companies call when a clear vision is needed to see them through complex cases in which patent issues are knotted up with regulatory and antitrust concerns. Brown is a lead member of a well-built cross-office team supporting Eagle on bringing to market and protecting a key pharmaceutical product; defending patent multiple patent litigations; obtaining FDA approval; litigating against the FDA; and filing offensive patent infringement claims against generic challengers. In another perfectly structured team, Clement Naples has been representing Xperi (formerly Tessera) in major competitor fights with Samsung, the settlement of which caused an immediate leap in Xperi’s share value.

Leason Ellis LLP

When it comes to quality and client service, Leason Ellis surpasses high expectations at every turn. The boutique has been surging on all fronts lately: as busy as ever on prosecution, it has been earning bigger, more sophisticated co-counsel and lead litigation instructions and returning the compliment with some superb results. Zooming in on the ensemble’s sterling prosecution and transactional offerings reveals a non-contentious practice in fine fettle – both on the life sciences side, anchored by Elizabeth Barnhard, Susie Cheng and Michael Davitz; and in high-tech, thanks to David Leason and Edward Ellis. Barnhard’s patenting efforts for drug companies have met with considerable success of late, capped by a winning appeal for Champalimaud Foundation of a subject-matter ineligibility USPTO objection regarding an invention directed to methods for determining effective cancer treatment. Cheng has been spearheading a flourishing Asia and China-facing practice and is acting for multiple research and technical institutions in Hong Kong. “Susie is an outstanding international patent and business partner. She clearly explains the best pathways to take and renders a world-class and timely service.” Davitz, a rare doctor of medicine in the IAM Patent 1000, has been prosecuting for Columbia University while proving his dealmaking dexterity for many others as a high-octane transactional lawyer. Managing partner Leason flexes one of the best-rounded practices in the group: he counsels across the IP spectrum, always with a creative and commercial touch. Fellow founder Ellis, who chairs the patent group, debuts in the guide this year, being highly recommended for his “combination of technical excellence and high-level strategic thinking”. Leading the line of a litigation group that is constantly growing in high-level experience, Yuval Marcus is a practical and efficient litigator who serves commercial needs first. The firm’s broader culture is entrepreneurial in this way; versatile lawyers such as Melvin Garner fly out to clients to see and learn about their products and operations, so that they can litigate disputes in a business-functional way. Robert Isackson is another seasoned trial hand who “gets the job done”. “Robert demonstrates a strategic intelligence around problem solving and demonstrates a sense of urgency in carrying out his instructions.”

Mayer Brown

With the dip in US patent litigation, firms have had to be agile in diversifying their offerings. Setting the pace in this regard is Mayer Brown, whose transactional practice has lately recorded impressive growth. The lawyers here analyse portfolios with the eyes of litigators to assess their strength and risk factors; they also know the lie of the land in their focused industry of the life sciences and, if a client acquires a drug, for example, can predict whether it will corner the market or face stiff competition. Increasingly engaged in deal work in this way are global IP co-chair Lisa Ferri and Brian Nolan, who advised Bristol-Myers Squibb on its $74 billion acquisition of Celgene, creating a heavyweight in oncology and immunotherapy drugs. Of course, given its entrenchment in the pharmaceutical scene, Mayer Brown continues to litigate with panache; Ferri often teams up effectively with inimitable litigation strategist and regulatory expert Richard McCormick. Smaller than a lot of contentious groups out there, they turn this into a strength and handle cases in a nimble, hands-on, partner-led manner.

Milbank LLP

Milbank elevated its national patent litigation practice significantly in 2019, hiring a team of high-powered former Irell partners in Los Angeles, including David Gindler and Gary Frischling. Already they have bedded in well in a top-calibre operation spearheaded out of New York by Christopher Gaspar and Errol Taylor. All four lawyers are cut from the same cloth, being worldly-wise trial hands with exceptional oral advocacy skills; together, they form a group that is “unparalleled in its ability to tackle the most multifaceted challenges”. Coming in for special praise, “Chris is not just a legal but a business expert, with an incredible depth of industry-specific knowledge. Amazing in every respect, he is a thoughtful, responsive and creative lawyer who uses all available resources to clients’ advantage”. Working primarily in the electrical, semiconductor, computer, fintech and medical device areas, “he pours passion into his cases and can be recommended in a heartbeat”. Taylor is the firm’s pharmaceutical doyen and the sort of “thorough and eminently capable” lawyer who can pull off major wins at trial and at the Federal Circuit that generate huge jumps in share price for the companies he represents.

Norton Rose Fulbright LLP

What Norton Rose Fulbright offers in the form of end-to-end US and global patent capabilities is incredibly rare. Its domestic IP group is home to 124 individuals with technical backgrounds, including 19 PhDs, creating the foundations of a precision prosecution platform. These technically proficient individuals include New York’s Gerard Messina, who patents and counsels across a broad spectrum of technologies, including computer hardware and software, semiconductors and telecoms. He plays a lead role on a team responsible for major prosecution for Robert Bosch, which transferred a portfolio of over 2,000 pending applications to the firm in 2016, a number of which relate to autonomous driving and AI. At any given time, Norton Rose Fulbright is also engaged in dozens of patent litigation battles across the country, giving it an excellent vantage point from which to assess legal and business developments and inform strategy. Right in the thick of it are Jeffrey Lewis and Paul Keller, who respectively focus on life sciences and chemistry and automotive and fintech. Both know their industries intimately and have gone the distance at trial multiple times.

O’Melveny & Myers LLP

O’Melveny’s New York patent litigation division maintains an exciting practice operating at the cutting edge of the life sciences. Young, nimble, forward thinking and flexible with respect to alternative fee arrangements, the crew offers tremendous value alongside outstanding results. Taking the reins is Lisa Pensabene, a “smart, creative, tough and tireless lawyer who has really become a first-rate advocate”. “Lisa and her team clearly enjoy what they do and are great fun to work with.” She has been leading multiple waves of Hatch-Waxman litigations against generic pharmaceutical companies for AstraZeneca, enforcing patents covering breast cancer treatment Faslodex, and litigating a series of cases for Onyx Therapeutics to enforce multiple patents relating to Kyprolis, another blockbuster cancer drug. With her on these matters is Hassen Sayeed, a medical doctor and experienced trial lawyer who lateralled to O’Melveny from Paul Hastings in 2018.

Paul Hastings LLP

Rightly priding itself on its strategic, detail-oriented and on-trend approach to litigation, Paul Hastings continues to fight – and win – cases of vital strategic importance for life sciences companies. Recently anointed as global co-chair of the IP practice, Bruce Wexler is building something special in New York and across offices in the form of a dynamic young team of litigators with the trial chops to lead on big matters just like he does. Entering prime time are Preston Ratliff II, Eric Dittmann, Chad Peterman and Isaac Ashkenazi, all of whom have proven themselves capable of besting large teams of seasoned lawyers from other well-resourced firms. With venerable branded pharmaceutical litigator Joseph O’Malley in support, Ratliff recently acted as lead counsel for Sucampo in multiple patent infringement actions against generic drug manufacturers to protect its Amitiza IBS drug. Dittmann, the global IP vice chair, has been performing admirably in a complex, multi-practice international arbitration that pitted client Mitsubishi Tanabe Pharma Corp against Novartis; representing the same company in Hatch-Waxman litigation, he showed his creative streak by developing a novel legal argument to defend against an obviousness-type double patenting challenge. Peterman is contributing immensely on electrical engineering and pharmaceutical cases; alongside Palo Alto star Yar Chaikovsky, he is currently defending Snap, Inc against allegations of patent infringement levelled by BlackBerry relating to mobile messaging technology – with Quinn Emanuel on the other side. Ashkenazi, who debuts in the IAM Patent 1000 for 2020, linked with Wexler and Dittmann to prevail for Boehringer Ingelheim against AbbVie in one of the largest litigations under the Biologics Price Competition and Innovation Act. In this, Paul Hastings’s 20-strong team went up against 70-plus lawyers across three mighty firms (WilmerHale, Latham and Finnegan), and pursued a shrewd litigation strategy that allowed Boehringer Ingelheim to jump the queue and enter the market before earlier-settling parties. Many of the set’s life sciences and technology clients require not only IP litigation, but also transactional support. They get this in spades from Samuel Waxman, who continues to carry out newsworthy work on research partnerships and other collaborations for Deerfield Management.

Paul Weiss Rifkind Wharton & Garrison LLP

Best known for its superior know-how in the life sciences, and specifically biologics, Paul Weiss is a class apart in patent litigation more broadly; the trial skills of its eminent practitioners are infinitely transferable, lending impressive diversity to the practice. Nicholas Groombridge, for example, is currently defending Twitter in a Central District of California suit in which BlackBerry is alleging infringement of multiple mobile advertising and messaging interface patents; he and DC lawyers Dave Ball and Steve Baughman have narrowed down the case from seven patents to four, with the others being dismissed on ineligible subject-matter grounds. At the same time, he is representing Amgen in multiple biosimilar litigations. Groombridge is solid gold in the IAM Patent 1000, being unanimously lauded as a “thoughtful and creative lawyer with a tremendous courtroom presence”. He also elevates the people around him – individuals such as Jennifer Wu and Eric Alan Stone have developed into strong leaders, thanks in no small part to the example he has set and his team mentality. Stone deputy co-chairs the patent litigation group with Catherine Nyarady, another unflappable litigator who can get the measure of the most technically complex cases.

Pearl Cohen Zedek Latzer Baratz 

International outfit Pearl Cohen has 55 patent specialists spread across offices in New York, Los Angeles, Tel Aviv, Haifa and London, and renders a premier 360-degree patent service to a colourful catalogue of clients, including dynamic start-ups, chart-topping companies and august universities and research institutions. Making a well-deserved debut in the IAM Patent 1000 for 2020, the firm’s New York line-up of Zeev Pearl, Mark S Cohen and Guy Yonay is a repository of trust for CEOs and Nobel prizewinning scientists alike. Founder and managing partner Pearl is a US patent agent and Israeli patent lawyer who gives satisfyingly rich global counsel related to licensing, SEPs and litigation, among other things. Mark Cohen - Life Sciences Chair and board member of cell therapies developer Masthercell Global – operates on a similar plane and is “a professional of the highest order when it comes to aligning business and patent strategy”. Yonay is the tip of the spear in litigation. He does not chase down all possible third parties and take depositions around the world in the hope that something will turn up; rather he is a highly focused strategist who runs cases leanly and cost effectively from the get-go. He and Pearl handle all of Telit Communications’ SEP matters, including negotiations and litigations, on a global basis, collaborating closely with colleagues in the United Kingdom and Israel.

Perkins Coie LLP

Flying the flag for Perkins Coie in New York are William McCabe and Gene Lee, two paragons of the firm’s vigorous, multiple industry-shaping patent litigation practice. Both have close ties to US and Asian companies and, as lead counsel, have secured major victories on domestic and foreign soil in widely contrasting technical fields.

Proskauer Rose LLP

Sought after for representation in important cases with plenty of meat on the bones, Proskauer’s patent litigators are in their element delving into knotty claim construction issues and thick books of expert evidence. Painstaking preparation and strategic vision help them shine at trial, too: the courtroom is an environment in which they are supremely comfortable, having gone the distance many times. Distinguished by the depth of his experience, James Shalek has litigated seminal cases going back decades. He marshals the facts very effectively and puts his points across clearly and persuasively without coming across like a salesman. Baldassare Vinti litigates with economy and efficiency; he considers every task through a trial lens and takes actions optimised to the desired results. Both demonstrate impressively wide technical acuity and perform with punch in the high-tech and life sciences realms. Helping to make the latter a strong suit of the wider organisation, managing partner and head of the interdisciplinary life science group Daryn Grossman tackles a diverse array of challenging transactional instructions, staying sharp and ready for the next deal in her stacked pipeline.

Quinn Emanuel Urquhart & Sullivan LLP

Quinn Emanuel is unrivalled in New York for the depth of its trial bench. “Quinn’s lawyers are always well prepared for court and worthy adversaries who fiercely but productively protect their clients – they don’t fight on every point and run up costs, but focus on resolving business problems.” Its most senior members in the Big Apple include Dominic Cerrito, Peter Armenio, Sandra Bresnick, Colleen Tracy James, Richard Erwine, Raymond Nimrod, Edward DeFranco, Thomas Pease and Kathleen Sullivan, all of whom bring something special to the table. Cerrito is “extremely aggressive, though he channels it effectively”; the feared advocate is a “smart, tenacious lawyer who can find any advantage” and “the person to hire for a true bet-the-company case”. He and Armenio both bring inspiring leadership to the life sciences practice, serving respectively as national and global co-chair – though their approaches are very different, Armenio’s being “thoughtful, cerebral and careful”. The firm’s pharmaceutical core is only getting stronger; rounding it out are Bresnick, James and new recruit Angus Chen, who joined in March 2020 from Haug Partners – each a sure bet when only a win will do. On the high-tech side, Erwine has been on a good run lately in the semiconductor space. “Rich combines technical dexterity with a smart, witty and personable style of advocacy – judges want to follow his lead.” Nimrod – who litigates across the technical spectrum, from pharmaceuticals to software – also has mesmeric power: “An exceptional lawyer, he has a commanding presence in the courtroom and is a powerful presenter; witnesses feel like they simply have to side with him.” National IP litigation group co-chair DeFranco is a big hitter in the wireless and telecoms, smartphone and semiconductor domains, among others, and can conduct textbook-worthy cross-examinations, too. Pease brings vital SEP and FRAND expertise to the practice; he is also noted for his international arbitration skills. Sullivan is one of the foremost appellate experts in the country.

Robins Kaplan LLP 

Top technology companies tie their flags to the mast of Robins Kaplan when existential threats arise in patent litigation form. Given the presence of trial lawyers such as Ronald J Schutz, it is not hard to see why: chair of the executive board and a fellow of the ACTL, Schutz is a natural-born leader with vast trial experience and a stellar record. The Minneapolis-based outfit has been gaining traction in the New York thanks to the efforts of Elizabeth Gardner, who came on board in late 2018; and Bryan J Vogel, who founded the local office. A pharmaceutical litigator of two decades’ standing, Gardner has significantly bolstered the Robins Kaplan life sciences offering. Vogel cuts a dash in the ITC and heads the firm’s Section 337 practice.

Ropes & Gray LLP

The arrival of Filko Prugo and Charlotte Jacobsen in early 2018 was an inflection point for Ropes & Gray in New York. They brought with them a potent and progressive life sciences patent litigation practice that has only gotten stronger since, fuelled by instructions from some of the most innovative pharmaceutical and biotech companies in the world. The value Prugo brings to litigation as a seasoned counsellor is immense, as shown by the successful pre-litigation resolution he recently secured for a client in an IP policy dispute implicating hundreds of millions of dollars in business. Arising out of their significant Hatch-Waxman litigation practice, he and Jacobsen are also often retained to advise companies on patent strategy with regard to the protection of next-generation drug candidates. When clients are in trouble, the pair swoop in and save the day – but they are just as brilliant at keeping them out of trouble, too. Steven Pepe also litigates with aplomb in the life sciences, as he recently showed through his staunch representation of Korean biotech entity CJ CheilJedang in an ITC investigation filed by competitor Ajinomoto; a ruling of non-infringement followed, which was affirmed in August 2019 by the Federal Circuit. However, Pepe’s technical compass is broad – he is just as devastatingly effective in semiconductor, telecommunications and other high-tech cases. Patent litigation luminary Jesse Jenner can also take any case through trial and emerge victorious.

Shearman & Sterling LLP

Shearman & Sterling’s expert panel of patent litigators continue to be involved in a flurry of important LED-related cases; Mark Hannemann and Thomas Makin, for example, are representing Nichia and OSRAM in a major ITC investigation. They know the technology and the industry well, so clients do not waste money having to teach them the ropes; they understand, too, that the plaintiffs they are facing are in it for the long haul and are well funded, so careful background research and smart planning are required for success. The pair have also lately distinguished themselves as top trade secret litigators; they have conscientiously cultivated their skillset in this burgeoning area and draw astutely on the expertise of other divisions of the firm for nuanced cases. A notable 2019 win here was jury verdict of $44 million ($16 million in compensatory damages; $28 million in punitive) for leading fintech software and services company SS&C Technologies in a trade secret misappropriation case against Clearwater Analytics. Hannemann and Makin play well off each other, Hannemann being the legal theory and strategy thinker, while Makin is the deep-dive technical guy; leveraging a strong cadre of associates, the two focus on getting clients what they need while minimising interruption to their business. Shearman & Sterling’s service capability extends from litigation to IP transactions. Chief deal-broker Jordan Altman negotiates complex deal terms with silky skill and has a lot to show for it. Advising the Dow Chemical Company in connection with its separation and spin-off from DowDuPont is one recent highlight. “Jordan can distil huge volumes of information quickly – if you give him a 100-page document, he’ll have a detailed summary of it together in a couple of hours. He responds immediately and is incredibly agile, forward thinking and solutions oriented.”

Sidley Austin LLP

Working within a well-run national group, Sidley Austin’s New York patent litigators dispatch high-value instructions with a level of assurance that comes only from great experience and many successful outcomes. Forming a pharmaceutical SWAT team, Jim Badke, Ching-Lee Fukuda and Sona De are making waves with their representations and results. Together, they secured a damages award for Bayer against Shire/Baxalta that counts as the largest biotech patent verdict in the District of Delaware and one of the 10 largest patent verdicts there in the past decade; this followed a six-day trial involving 18 witnesses in which the jury found all asserted claims of Bayer’s patent covering a biologic product for the treatment of haemophilia both infringed and valid. Mirroring her litigation colleagues’ success on the deal side, technology and IP transactions global co-leader Jennifer Coplan has had plenty to talk about, too. Given the rise of data as a business asset, advising Two Sigma Investments in its strategic partnership with leading data engineering and information supply chain operator Crux Informatics is a perfect example of the cutting-edge work she does.

Skadden Arps Slate Meagher & Flom LLP

Rigorously commercial in its approach to intellectual property, prestigious Skadden has a consummate mastery of IP and technology transactions. High-rolling deals have been coming thick and fast for its acclaimed specialists, but the side has no problem keeping up with the pace. During the review period, Resa Schlossberg – who comes from a molecular biophysics and biochemistry educational background – hit fifth gear on life sciences matters, advising Gilead Sciences and cell therapy substitute Kite Pharma on their $567 million acquisition of Cell Design Labs; Vertex Pharmaceuticals on its $950 million acquisition of Semma Therapeutics; Alder Biopharmaceuticals on its $1.95 billion acquisition by H Lundbeck; and DowDuPont on the $21.6 billion spin-off of its agricultural division and the $42 billion spin-off of its materials science division. Jose Esteves, meanwhile, is advising Intel on its $1 billion sale of its smartphone modem business to Apple and representing Exact Sciences Corporation on is $2.8 billion acquisition of Genomic Health; and recently acted for Dassault Systèmes in its $5.8 billion acquisition of Medidata Solutions. For his part, co-head of the IP and technology group Stuart Levi has been spearheading Skadden’s work in the blockchain, outsourcing and privacy areas. Not to be outdone, litigators Douglas Nemec and Anthony Sammi have also been doing great things – for example, settling ZeniMax Media’s high-profile dispute with Facebook and Oculus, in the course of which they obtained a $500 million jury verdict for ZeniMax.  They have been representing Caterpillar in several cases, too.

Steptoe & Johnson LLP

Steptoe’s healthcare and life sciences industry group is a discerning choice for pharmaceutical and biotech companies seeking full product lifecycle support. A counsellor and portfolio manager par excellence, Ying Li is one of their first ports of call. “Ying’s patent writing style is concise and tells a story. She delivers a top-quality work product and always delivers under extremely tight deadlines. She is extremely knowledgeable in areas such as viral vectors, cell therapy and gene editing, and is also excellent at interfacing with business management, getting to the critical points quickly and providing valuable strategic guidance.” Her many duties include representing Sanofi in prosecution in several therapeutic areas, including immuno-oncology and multiple sclerosis. When there are battles to be fought and won, patrons turn to head of New York intellectual property John Molenda and Vishal Gupta, both “extremely smart and meticulous lawyers who get deep into the tech”. The brand they have created is a strong one, on both the small and large molecule sides. Particularly eye-catching is their work for Sanofi and Regeneron against Amgen in defending claims of patent infringement against antibody therapy Praluent; upon remand from the Federal Circuit, in a recent trial they succeeded in invalidating all five patent claims asserted by Amgen. Molenda and Gupta also work integrally on many Apotex cases.

Sullivan & Cromwell LLP

Time and again, companies turn to Sullivan & Cromwell to take care of the things that are most important to them. It wins a disproportionate percentage of its cases and has a cadre of imaginative, highly trained and talented lawyers who are good in the courtroom and in business. The set’s litigation style is distinctive, as its senior lawyers live their cases from the start to their ultimate resolution; Garrard Beeney, the most senior, picks up a case when it is filed, not when it is tried, and learns the record and the facts to craft customised strategies. Beeney does this with “exceptional integrity” too and is admired as a “complete gentleman who is very respectful with all parties and witnesses to a litigation”. Lately, he has undertaken extensive litigation for Via Licensing against various parties, while also representing BlackBerry in litigation against Nokia and Columbia University against Symantec. Notable, too, is the niche he is carving out for Sullivan & Cromwell in the cellular connectivity area: the firm is being called on to address many issues arising in the context of 5G, the implementation of which it is smoothing while avoiding the friction that can be caused by the filing of lawsuits. In this and in other ways, Beeney contributes to one of the best patent and technology transactions practice in the country. Alongside him is Mehdi Ansari, who locks down multibillion-dollar deals on the daily. Together with Palo Alto superstar Nader Mousavi, he advised Bayer on the IP aspects of its $66 billion acquisition of Monsanto – the largest completed all-cash takeover in history. Another linchpin on genre-defining transactions is cybersecurity and IP and technology group co-head John Evangelakos.

Venable LLP

Having now slotted all the pieces into place following its Summer 2018 addition of Fitzpatrick’s lawyers, Venable is riding high in patent litigation right now. Surfing the crest of the wave are New Yorkers Dominick Conde and William Solander, who anchor a robust pharmaceutical litigation practice. Both garner plaudits from the market – Conde as a “super-tactical counsellor and fair and reasonable litigator”, while Solander as an “experienced, efficient, cost-effective and business-focused lawyer with a high rate of success”. Connecting well to build impregnable fortresses, they successfully defended the validity of a patent covering Sanofi’s Jevtana chemotherapy product at the Federal Circuit in an appeal arising out of an earlier trial win. Conde has also been working closely with new IAM Patent 1000 inclusion and versatile life sciences and high-tech advocate Christopher Borello; one of their joint wins was an $89.7 million jury verdict for Vectura. Scott Reed is another engine of a life sciences practice with incredible horsepower; he was central to the global settlement of litigation between client Alnylam Pharmaceutical and Silence Therapeutics under which Alnylam obtained a non-exclusive irrevocable licence to all Silence patents relevant to its products. Achieving similar feats on the high-tech side, Michael Sandonato has been busy at the ITC, acting for LILLEbaby in an investigation of trade violations committed by 25-plus companies importing infringing child carriers into the United States. With him on this is Frank Gasparo, the head of intellectual property for the New York office and co-chair of the IP litigation group. Taking the reins of Venable’s respected IP transactions unit with DC-based Nora Garrote, Alicia Russo handles high-profile acquisitions and licensing mandates with distinction. Russo excels at issue spotting and problem solving in the context of large and small molecule life sciences deals.

Weil, Gotshal & Manges LLP 

The superlative patent and technology transactions division at Weil enjoyed a red-letter year in 2019. Routinely instructed on the sorts of non-commodity deals that have the undivided attention of company CEOs and boards, its 24-strong dedicated group – one of, if not the largest in the country – consistently changes the game for life sciences, financial services and high-tech entities. Forming an elite squad together with Silicon Valley’s Karen Ballack are Michael Epstein, Jeffrey Osterman and Charan Sandhu. Epstein, the stalwart leader of the group, has a natural flair for business and brings a full appreciation of the bigger commercial picture to each deal; he is also fearless when it comes to stating his view – both reasons why those who could hire anyone hire him. He recently led on multiple large transactions for Campbell Soup Company. Representing Eli Lilly is the predominant focus for Osterman; he has advised the company on its approximately $8 billion acquisition of Loxo Oncology and its global licensing and research collaboration with an affiliate of ImmuNext. Sandhu’s work cannot be reported on for reasons of confidentiality, but includes major settlement, supply and technology development and joint venture restructuring transactions. Sources call her a “trusted adviser and steady leader in complex negotiations”. Weil’s litigators operate on a similarly lofty plane and are go-tos for big-ticket disputes between competitors; Elizabeth Stotland Weiswasser and Anish Desai’s multilayered representation of Johnson & Johnson against Intuitive Surgical in ITC, District of Delaware and PTAB proceedings is a good example in this regard. Weiswasser is a life sciences star with a strong technical foundation, while Desai comes from an electrical engineering background but can handle anything; together, they make a formidable team.

White & Case LLP 

White & Case is one of only five firms in the IAM Patent 1000 New York rankings with multiple individuals recommended for litigation and transactions, and the only one with three-plus representatives on each; its strength in depth across the two practice areas is a major USP. Two of its number – transactional maven Erin Hanson and poised litigator Alison Hanstead – make well-deserved debuts this year, in recognition of their growing impact in the firm and on the wider market. Hanson brings valuable international experience to the table and is a proven performer in the context of cross-border IP and technology-driven corporate and standalone deals. She joins fellow strategic global deal brokers Adam Chernichaw and Arlene Arin Hahn in the guide. Hanstead is a seasoned Hatch-Waxman litigator with deep industry knowledge. She has brought the heat extensively for Pfizer alongside fellow trial lawyers Dimitrios Drivas and Raj Gandesha, with whom she forms a compelling pharmaceutical patent litigation unit, well suited to the most complex and antitrust-significant cases. Scott T Weingaertner is the key contact for litigation in the telecommunications, internet, software and hardware areas; he works hard and smart in district courts and the ITC, and is great at getting large teams both within and outside White & Case pulling in the same direction.

Wilmer Cutler Pickering Hale and Dorr LLP

“A top firm with some of the best patent litigators in the country” is the unanimous verdict on WilmerHale. Exceptional at navigating uncharted territory for cutting-edge innovators, the firm has, for example, been on the frontlines of major litigation under the Biologics Price Competition and Innovation Act. New York’s Robert Gunther – partnering with dignitaries William Lee and Lisa Pirozzolo, among others – is handling biosimilar litigation for Genetech involving its $7 billion per year breast and gastric cancer drug Herceptin. Gunther is a veteran pathfinder and fellow of the ACTL. David Bassett achieves great things in life sciences, too; acting for Gilead, he saw to the denial of 10 straight inter partes review petitions filed by the Initiative for Medicines, Access & Knowledge – a particularly impressive result given the approximately 60% institution rate for pharmaceutical patents.

Winston & Strawn LLP 

The importance of knowing the product line from top to bottom in litigation can get underplayed or pushed down; at Winston, however, every member of a trial team – from the most senior to the most junior – is expected to have that product and business understanding, and to roll up their sleeves and dig in from the moment that a case is filed. As a result of this approach, the firm cultivates close relationships with clients, which come not just for representation, but for steady advice. Immeasurably helpful in this regard is Pejman Sharifi, an accomplished prosecutor and counsellor whose job it is to build the intangible assets over which companies fight. Rounding out the award-winning litigation practice in New York are Michael Murray and Krishnan Padmanabhan. A true patent lawyer and courtroom advocate, Murray stands apart for his combination of substantive patent law knowledge, technical dexterity and trial capability. Padmanabhan is coming on strong in telecoms, new media and technology, and is keeping the Winston team at the vanguard of these sectors, partly through his impressive ITC endeavours.

Other recommended experts

Former Arnold & Porter lawyer James Blank has been doing his thing at Baker McKenzie since the start of 2019, litigating with dexterity in district courts, at the PTAB and at the Federal Circuit. He is accustomed to meeting and exceeding the contentious needs of a high-level international client base for which intellectual property is pivotal. Karen Bromberg and Francisco Villegas of Cohen & Gresser are endorsed by international sources as “excellent IP strategists”. Bromberg shows a talent for “resolving complicated matters in creative and business-minded ways”. She is representing FirePASS in patent litigation and, together with Villegas, has successfully enforced its patent portfolio against Boeing and Honeywell. Laura Brutman spearheads patent prosecution activities at Schiff Hardin. “Laser-focused on quality, she’s extremely consistent in the practice.” Elevating Orrick’s brand in New York are Joseph Calvaruso and Joshua Rosenkranz. Calvaruso pulls no punches in the courtroom, but is a tactical fighter who picks the right battles. When it comes to appellate advocacy, “nobody is smarter or more creative” than Rosenkranz. With Arlene Chow and Adam Golden on deck, Hogan Lovells is well equipped for patent litigation and transactions. Chow is a seasoned first-chair trial lawyer for pharmaceutical companies, whose success stems from a sophisticated scientific understanding and an innate ability to distil the complex down to its essence. Golden is also a servant to the life sciences industry as a skilled M&A, licensing and collaborations lawyer. Locke Lord is on the rise and has been recruiting well – for example, adding appellate and post-grant ace Steve Trybus from Jenner in Chicago. Alan Clement has been making all the right moves as chair of the IP department and in his role as a high-level life sciences counsellor and trial lawyer. Peter Fill is also fuelling the firm’s success as co-chair of the patent strategies group. Captaining Cooley’s global patent counselling and prosecution practice, Ivor Elrifi can “efficiently handle litigation issues and facilitate conversations between companies seeking flotations and underwriters. He’s excellent at getting everyone on the same page and not overanalysing things that don’t require it”. Christopher Harnett recently landed at Maynard Cooper & Gale. The veteran patent trial lawyer is great on science and business and a respected name in the life sciences domain. David Hecht does everything humanly possible to keep clients happy and deliver the wins they seek – and he loves it. Entrepreneurial, tenacious and motivational, he does a superb job carrying the day in high-exposure computer, software, communications and medical technology cases. He recently set up Hecht Partners and assembled a team with great trial talent and experience. A new member of Panitch Schwarze Belisario & Nadel’s team, Philip Hirschhorn does a terrific job diving into diverse technologies and working out how best to present them to juries and PTAB judges. Lately he has been teaming up dynamically with DC’s Matthew Fedowitz in the biopharmaceutical context. Pryor Cashman’s Jeffrey Johnson is in tune with evolving industries, including cannabis, entertainment, software and life sciences; his gift is the ability to create IP value, which puts him in demand as a strategic counsellor and transactional lawyer. Lori Lesser heads the IP transactions practice at Simpson Thacher. She has razor-sharp negotiation skills and has sealed patent and technology deals of all stripes and colours. Her knowledge of litigation, privacy and cybersecurity issues enables her to see a transaction from all angles. Willkie Farr IP chair Thomas Meloro is a trusted confidant to top life sciences companies, for which he litigates cases involving blockbuster products. He is supremely poised as a trial and appellate lawyer. Michael Mercanti is technically adept and business savvy in equal measure. The crackerjack pharmaceutical patent strategist is co-founder of Lucas & Mercanti, a compact Lower Manhattan boutique with global horizons and an international reputation for quality. Katten’s national patent litigation co-chair Deepro Mukerjee is a force to be reckoned with in pharmaceutical disputes. Much admired for his spirited representation in Hatch-Waxman suits, Mukerjee does much more than just litigate and is someone to dial up for business-infused counsel. Radulescu LLP’s singular mission is to win complicated, high-exposure patent cases, and founding partner David Radulescu makes this a fait accompli – he has all the trial experience you could ask for, and an outstanding track record to show for it. Harry Rubin chairs the technology and IP transactions practice at Kramer Levin – he is a must for complex international deals and a fintech authority. Kenneth Sonnenfeld and Margaret Brivanlou recently joined Ballard Spahr from King & Spalding. Both are long-time repositories of trust for pharmaceutical companies, with a panoramic perspective on their business and legal needs. Both also have PhDs – Sonnenfeld’s in pharmacology and Brivanlou’s in molecular biology. One of Susman Godfrey’s potent weapons, Arun Subramanian is a future leader of the patent litigation bar. He has experience beyond his years, litigating must-win cases on both sides of the ‘v’. Charles Weiss “is unmatched in his ability to advise from scientific, legal, regulatory and business perspectives. He is uniquely skilled at transitioning from the boardroom to the courtroom and one of the few lawyers who can try cases and be relied on in a commercial negotiation.” The life sciences authority practises at Holland & Knight.

Individuals: litigation

  • Peter J Armenio PC - Quinn Emanuel Urquhart & Sullivan LLP
  • Gregory S Arovas - Kirkland & Ellis LLP
  • Garrard R Beeney - Sullivan & Cromwell LLP
  • Paul A Bondor - Desmarais LLP 
  • F Dominic Cerrito - Quinn Emanuel Urquhart & Sullivan LLP
  • Robert V Cerwinski - Goodwin Procter LLP
  • Evan R Chesler - Cravath, Swaine & Moore LLP 
  • Dominick Conde - Venable LLP
  • Edward J DeFranco - Quinn Emanuel Urquhart & Sullivan LLP
  • John M Desmarais - Desmarais LLP 
  • Dimitrios T Drivas - White & Case LLP
  • Gerald J Flattmann Jr - King & Spalding LLP
  • Nicholas Groombridge - Paul Weiss Rifkind Wharton & Garrison LLP
  • Robert J Gunther - Wilmer Cutler Pickering Hale and Dorr LLP
  • Edgar H Haug - Haug Partners LLP
  • Elizabeth J Holland - Goodwin Procter LLP
  • Keith R Hummel - Cravath, Swaine & Moore LLP 
  • Josh Krevitt - Gibson Dunn & Crutcher LLP
  • Joseph M O'Malley - Paul Hastings LLP
  • E Joshua Rosenkranz - Orrick, Herrington & Sutcliffe LLP
  • Kathleen M Sullivan - Quinn Emanuel Urquhart & Sullivan LLP
  • Errol B Taylor - Milbank LLP
  • Bruce M Wexler - Paul Hastings LLP
  • Mark J Abate - Goodwin Procter LLP
  • Robert A Appleby - Kirkland & Ellis LLP
  • Jim Badke - Sidley Austin LLP
  • David K Barr - Arnold & Porter Kaye Scholer LLP
  • David Bassett - Wilmer Cutler Pickering Hale and Dorr LLP
  • Matthew Becker - Axinn, Veltrop & Harkrider LLP 
  • Scott J Bornstein - Greenberg Traurig LLP
  • Sandra A Bresnick - Quinn Emanuel Urquhart & Sullivan LLP
  • Daniel G Brown - Latham & Watkins LLP
  • Patricia Carson - Kirkland & Ellis LLP
  • James W Dabney - Hughes Hubbard & Reed LLP
  • Daniel P DiNapoli - Arnold & Porter Kaye Scholer LLP
  • Eric W Dittmann - Paul Hastings LLP
  • Richard Erwine - Quinn Emanuel Urquhart & Sullivan LLP
  • Lisa Ferri - Mayer Brown
  • Porter F Fleming - Haug Partners LLP
  • John Flock - Hunton Andrews Kurth LLP
  • Christopher J Gaspar - Milbank LLP
  • David Greenwald - Cravath, Swaine & Moore LLP 
  • Benjamin Hershkowitz - Gibson Dunn & Crutcher LLP
  • Colleen Tracy James - Quinn Emanuel Urquhart & Sullivan LLP
  • Alan S Kellman - Desmarais LLP 
  • Chad Landmon - Axinn, Veltrop & Harkrider LLP 
  • Michael J Lennon - Hunton Andrews Kurth LLP
  • Ira J Levy - Goodwin Procter LLP
  • Jeffrey ID Lewis - Norton Rose Fulbright LLP
  • Robert Maier - Baker Botts LLP
  • David R Marriott - Cravath, Swaine & Moore LLP 
  • Jonas R McDavit - Desmarais LLP 
  • Kevin X McGann - Fenwick & West LLP
  • Thomas J Meloro - Willkie Farr & Gallagher LLP
  • John J Molenda - Steptoe & Johnson LLP
  • Deepro R Mukerjee - Katten Muchin Rosenman LLP
  • Clement Naples - Latham & Watkins LLP
  • Douglas R Nemec - Skadden Arps Slate Meagher & Flom LLP
  • Raymond N Nimrod - Quinn Emanuel Urquhart & Sullivan LLP
  • John Normile - Jones Day
  • Catherine Nyarady - Paul Weiss Rifkind Wharton & Garrison LLP
  • Jeffrey Oelke - Fenwick & West LLP
  • Thomas Pease - Quinn Emanuel Urquhart & Sullivan LLP
  • Lisa B Pensabene - O’Melveny & Myers LLP
  • Chad Peterman - Paul Hastings LLP
  • Filko Prugo - Ropes & Gray LLP
  • Stephen S Rabinowitz - Dechert LLP
  • David C Radulescu - Radulescu LLP
  • Paul Ragusa - Baker Botts LLP
  • Preston K Ratliff II - Paul Hastings LLP
  • Scott K Reed - Venable LLP
  • Daniel L Reisner - Arnold & Porter Kaye Scholer LLP
  • P Anthony Sammi - Skadden Arps Slate Meagher & Flom LLP
  • Michael P Sandonato - Venable LLP
  • Robert C Scheinfeld - Baker Botts LLP
  • Ronald J Schutz - Robins Kaplan LLP 
  • James Shalek - Proskauer Rose LLP
  • Neil Sirota - Baker Botts LLP
  • Brian V Slater - Haug Partners LLP
  • William E Solander - Venable LLP
  • Richard J Stark - Cravath, Swaine & Moore LLP 
  • Aaron Stiefel - Arnold & Porter Kaye Scholer LLP
  • Eric Stone - Paul Weiss Rifkind Wharton & Garrison LLP
  • Daniel J Thomasch - Gibson Dunn & Crutcher LLP
  • Bryan J Vogel - Robins Kaplan LLP 
  • Charles A Weiss - Holland & Knight LLP
  • Elizabeth Stotland Weiswasser - Weil, Gotshal & Manges LLP
  • Huiya Wu - Goodwin Procter LLP
  • Allison Altersohn - King & Spalding LLP
  • Isaac Ashkenazi - Paul Hastings LLP
  • James S Blank - Baker McKenzie
  • Christopher Borello - Venable LLP
  • Karen Bromberg - Cohen & Gresser LLP
  • Joseph A Calvaruso - Orrick, Herrington & Sutcliffe LLP
  • Angus Chen - Quinn Emanuel Urquhart & Sullivan LLP
  • Arlene L Chow - Hogan Lovells
  • Natalie C Clayton - Alston & Bird LLP
  • Alan Clement - Locke Lord LLP
  • Rose Cordero Prey - Greenberg Traurig LLP
  • Sona De - Sidley Austin LLP
  • Anish Desai - Weil, Gotshal & Manges LLP
  • Evan Diamond - King & Spalding LLP
  • Peter N Fill - Locke Lord LLP
  • Ching-Lee Fukuda - Sidley Austin LLP
  • Adam Gahtan - Fenwick & West LLP
  • Raj Gandesha - White & Case LLP 
  • Elizabeth Gardner - Robins Kaplan LLP 
  • Melvin C Garner - Leason Ellis LLP
  • Frank M Gasparo - Venable LLP
  • Vishal C Gupta - Steptoe & Johnson LLP
  • Mark Hannemann - Shearman & Sterling LLP
  • Alison Hanstead - White & Case LLP 
  • Christopher J Harnett - Maynard Cooper & Gale
  • David Hecht - Hecht Partners LLP
  • Jeanne M Heffernan - Kirkland & Ellis LLP
  • Katherine A Helm - Dechert LLP
  • Pablo D Hendler - Jones Day
  • Philip Hirschhorn - Panitch Schwarze Belisario & Nadel LLP
  • Robert M Isackson - Leason Ellis LLP
  • Charlotte Jacobsen - Ropes & Gray LLP
  • Patrice P Jean - Hughes Hubbard & Reed LLP
  • Allan A Kassenoff - Greenberg Traurig LLP
  • Paul Keller - Norton Rose Fulbright LLP
  • Gene W Lee - Perkins Coie LLP
  • Noah M Leibowitz - Dechert LLP
  • Jane Love - Gibson Dunn & Crutcher LLP
  • Thomas R Makin - Shearman & Sterling LLP
  • William J McCabe - Perkins Coie LLP
  • Richard McCormick - Mayer Brown
  • Michael M Murray - Winston & Strawn LLP
  • Brian W Nolan - Mayer Brown
  • Karim Z Oussayef - Desmarais LLP 
  • Tamir Packin - Desmarais LLP 
  • Krishnan Padmanabhan - Winston & Strawn LLP
  • Thomas Parker - Leason Ellis LLP
  • Steven Pepe - Ropes & Gray LLP
  • Richard C Pettus - Greenberg Traurig LLP
  • Joshua L Raskin - Greenberg Traurig LLP
  • Brian Rosenthal - Gibson Dunn & Crutcher LLP
  • Hassen Sayeed - O’Melveny & Myers LLP
  • David Silverstein - Axinn, Veltrop & Harkrider LLP 
  • Kenneth H Sonnenfeld - Ballard Spahr LLP
  • Laurie N Stempler - Desmarais LLP
  • Arun Subramanian - Susman Godfrey LLP
  • James Trainor - Fenwick & West LLP
  • Robert W Trenchard - Gibson Dunn & Crutcher LLP
  • Clifford A Ulrich - Hunton Andrews Kurth LLP
  • Alexandra Valenti - Goodwin Procter LLP
  • Francisco A Villegas - Cohen & Gresser LLP
  • Baldassare Vinti - Proskauer Rose LLP
  • Scott T Weingaertner - White & Case LLP 
  • Calvin Wingfield - Goodwin Procter LLP
  • Jennifer H Wu - Paul Weiss Rifkind Wharton & Garrison LLP
  • Vanessa Yen - King & Spalding LLP
  • Guy Yonay - Pearl Cohen Zedek Latzer Baratz 
  • Michael T Zoppo - Fish & Richardson

Individuals: prosecution

  • Carl A Morales PhD - Dechert LLP
  • Samuel B Abrams - Dechert LLP
  • Adriane M Antler - Jones Day
  • Jonathan D Ball - Greenberg Traurig LLP
  • Elizabeth Barnhard - Leason Ellis LLP
  • Samuel Borodach - Fish & Richardson
  • Jack Brennan - Fish & Richardson
  • Margaret Brivanlou - Ballard Spahr LLP
  • Daniel R Brownstone - Fenwick & West LLP
  • Laura C Brutman - Schiff Hardin LLP
  • Susie S Cheng - Leason Ellis LLP
  • Mark S Cohen - Pearl Cohen Zedek Latzer Baratz 
  • Michael A Davitz - Leason Ellis LLP
  • Ivor R Elrifi - Cooley LLP
  • Melvin C Garner - Leason Ellis LLP
  • Joseph M Guiliano - Haley Guiliano LLP
  • James F Haley Jr - Haley Guiliano LLP
  • Daniel Hulseberg - Baker Botts LLP
  • David Leason - Leason Ellis LLP
  • Ying Li - Steptoe & Johnson LLP
  • Janet MacLeod - Fox Rothschild LLP
  • Karen Mangasarian - Haley Guiliano LLP
  • Michael Mercanti - Lucas & Mercanti LLP
  • Gerard Messina - Norton Rose Fulbright LLP
  • Zeev Pearl - Pearl Cohen Zedek Latzer Baratz 
  • Paul Ragusa - Baker Botts LLP
  • Pejman Sharifi - Winston & Strawn LLP
  • Deborah A Somerville - Fox Rothschild LLP
  • Kenneth H Sonnenfeld - Ballard Spahr LLP
  • Clifford A Ulrich - Hunton Andrews Kurth LLP
  • Tony Zhang - Fish & Richardson

Individuals: transactions

  • Garrard R Beeney - Sullivan & Cromwell LLP
  • Michael A Epstein - Weil, Gotshal & Manges LLP
  • David J Kappos - Cravath, Swaine & Moore LLP 
  • Lori Lesser - Simpson Thacher & Bartlett LLP
  • Stuart D Levi - Skadden Arps Slate Meagher & Flom LLP
  • Jeffrey Osterman - Weil, Gotshal & Manges LLP
  • Charan J Sandhu - Weil, Gotshal & Manges LLP
  • Charles A Weiss - Holland & Knight LLP
  • Jordan Altman - Shearman & Sterling LLP
  • Mehdi Ansari - Sullivan & Cromwell LLP
  • Frank J Azzopardi - Davis Polk & Wardwell LLP
  • Elizabeth Barnhard - Leason Ellis LLP
  • David Bauer - Davis Polk & Wardwell LLP
  • Adam Chernichaw - White & Case LLP 
  • Mark S Cohen - Pearl Cohen Zedek Latzer Baratz 
  • Jennifer B Coplan - Sidley Austin LLP
  • Ivor R Elrifi - Cooley LLP
  • Jose A Esteves - Skadden Arps Slate Meagher & Flom LLP
  • John Evangelakos - Sullivan & Cromwell LLP
  • Adam H Golden - Hogan Lovells
  • Daryn A Grossman - Proskauer Rose LLP
  • Arlene Arin Hahn - White & Case LLP 
  • Erin Hanson - White & Case LLP 
  • Daniel Hulseberg - Baker Botts LLP
  • Jeffrey C Johnson - Pryor Cashman LLP
  • David Leason - Leason Ellis LLP
  • Michael J Lennon - Hunton Andrews Kurth LLP
  • David MacDonald - Kirkland & Ellis LLP
  • Zeev Pearl - Pearl Cohen Zedek Latzer Baratz 
  • Thomas Pease - Quinn Emanuel Urquhart & Sullivan LLP
  • Paul Ragusa - Baker Botts LLP
  • Harry Rubin - Kramer Levin Naftalis & Frankel LLP
  • Alicia Russo - Venable LLP
  • Resa K Schlossberg - Skadden Arps Slate Meagher & Flom LLP
  • Pejman Sharifi - Winston & Strawn LLP
  • Kenneth H Sonnenfeld - Ballard Spahr LLP
  • Samuel Waxman - Paul Hastings LLP


  • Jesse J Jenner - Ropes & Gray LLP